WCN26-2012 Clinical Efficacy and Mechanistic Insights of Telitacicept Combined with Glucocorticoids in Adult-Onset Henoch-Schönlein Purpura Nephritis: A Case Report

Read full text Summarise with VIRAT
Authors: SHUNIAN GUO, Shu Rong
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Henoch-Schönlein purpura nephritis (HSPN), a severe renal manifestation of IgA vasculitis (IgAV), is rare in adults and associated with high morbidity. Current therapies are suboptimal, necessitating novel approaches. This case study evaluates the efficacy of telitacicept—a dual BAFF/APRIL inhibitor approved for systemic lupus erythematosus (SLE)—in a high-risk adult HSPN patient, aiming to explore its potential for IgA-mediated disorders.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106183–106183
Publication date
25 March 2026
Language
EN